Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide

Quan，Rencui1; Zhang，Huaqing2; Li，Zihuang1; Li，Xianming1

2020

10.1097/MD.0000000000018591

MEDICINE   影响因子和分区

0025-7974

1536-5964

This analysis aimed to investigate whether the long-term administration of temozolomide (TMZ) claimed a survival advantage for patients with glioblastoma in China.A total of 75 patients with newly diagnosed glioblastoma at the Department of Radiation Oncology, Shenzhen People's Hospital between August 2008 and August 2016 were retrospectively evaluated during analysis. A propensity-matched analysis was performed to balance the basic characteristics of patients between compared groups. Kaplan-Meier method and Cox proportional hazards model were used to assess progression-free survival (PFS) and overall survival (OS) of patients receiving 6 adjuvant TMZ cycles compared with patients treated with more than 6 cycles.Twenty of 75 patients received more than 6 cycles of TMZ, and the other 55 patients were treated with a median of 6 cycles ranging from 1 to 6. The patients with long-term administration of TMZ had better OS (47.0 months, 95% CI 20.0-73.9 vs 20.6 months, 95% CI 17.9-23.2, P = .014) but not PFS (17.0 months, 95% CI 10.1-24.5 vs 14.2 months, 95% CI 11.8-16.6, P = .133). Balancing the clinical factors with a propensity-matched analysis also showed the significant advantage of prolonged TMZ application in terms of OS but not PFS.Prolonged administration of TMZ beyond 6 cycles did demonstrate survival benefits for patients with initially diagnosed glioblastoma.

glioblastoma long-term administration overall survival progression-free survival temozolomide

SCI

英语

其他

WOS:000525864100029

CLINICAL MEDICINE

2-s2.0-85077733283

Scopus

1.Department of Radiation Oncology,Second Clinical Medical College of Jinan University,Shenzhen People's Hospital,Shenzhen,China
2.Department of Endocrinology,Hospital of Southern University of Science and Technology,Shenzhen,China

Quan，Rencui,Zhang，Huaqing,Li，Zihuang,et al. Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide[J]. MEDICINE,2020,99(2).

Quan，Rencui,Zhang，Huaqing,Li，Zihuang,&Li，Xianming.(2020).Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide.MEDICINE,99(2).

Quan，Rencui,et al."Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide".MEDICINE 99.2(2020).